Prognostic role of biomarker-glycoprotein in diagnostics of pathological changes in patients with arterial hypertension and diabetes mellitus 2 type

Authors

DOI:

https://doi.org/10.15587/2519-4798.2017.102545

Keywords:

arterial hypertension, diabetes mellitus type 2, insulin resistance, cardiovascular remodeling, galectin-3

Abstract

Aim – To study the influence of galectin-3 level on metabolic disorders progression and structural-functional changes of myocardium and vessels in patients with the associated course of arterial hypertension (AH) and diabetes mellitus (DM) type 2.

Materials and methods. Under conditions of the specialized department of arterial hypertension and kidney diseases SI “Institute of therapy, named after L.T. Malaya, AMS of Ukraine” were examined 92 patients with AH of II stage, 2 degree. They were divided in groups:  1 group – patients with AH without disorders of carbohydrate metabolism; 2 group – patients with AH and pre-diabetes; 3 group with the associated course of AH and DM type 2. The control group was maximally comparable with the studied one by age and sex.

There were examined the parameters of carbohydrate metabolism, insulin resistance and galectin-3 level. The echocardiography with the heart functional state determination was carried out. For the assessment of the thickness of the general carotid intima-media complex, the duplex ultrasound scanning was realized.

Results: In patients of 2 and 3 group was reveled the positive correlation between the insulin level of peripheral blood, hypertrophy of the left ventricle myocardium and the thickness of the general carotid intima-media. Hypertrophy of the left ventricle myocardium was more expressed in patients with AH and DM type 2 comparing with ones of 1 and 2 groups and the control group (р<0,05). Galectin-3 level was higher in the group with associated course of AH and DM types 2 than in 1 and 2 group and the control one (р<0,05).The positive correlation between galectin-3 level and insulin resistance parameters and structural-functional of vessels and heart remodeling was observed.  

Conclusions. It was established that the increase of galectin-3 level in blood serum may participate in insulin resistance progression, myocardium and vascular wall remodeling in patients with the isolated AH and with the associated course of AH and DM type 2

Author Biographies

Olexandr Bilovol, Kharkiv National Medical University Nauky ave., 4, Kharkiv, Ukraine, 61022

MD, Professor, Academician of National Academy of Sciences of Ukraine

Department of Clinical Pharmacology

Lesya Bobrotonnikova, Харьковский национальный медицинский университет пр. Науки, 4, г. Харьков, Украина, 61022

MD, Professor

Department of Clinical Pharmacology

References

  1. Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M. et. al. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 31 (7), 1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc
  2. Betteridge, D. J. (2001). Epidemiology of cardiac complications of type 2 Diabetes mellitus. Mediographia, 23, 95–99.
  3. Aroor, A. R., Mandavia, C. H., Sowers, J. R. (2012). Insulin Resistance and Heart Failure. Heart Failure Clinics, 8 (4), 609–617. doi: 10.1016/j.hfc.2012.06.005
  4. Huxley, R., Barzi, F., Woodward, M. (2006). Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ, 332 (7533), 73–78. doi: 10.1136/bmj.38678.389583.7c
  5. Blacher, J., Staessen, J. A., Girerd, X., Gasowski, J., Thijs, L., Liu, L. et. al. (2000). Pulse Pressure Not Mean Pressure Determines Cardiovascular Risk in Older Hypertensive Patients. Archives of Internal Medicine, 160 (8), 1085–1089. doi: 10.1001/archinte.160.8.1085
  6. Ruden, I., Standi, E., Barnic, M. et. al. (2012). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. The Task Forse on Diabetes and Cardiovascular Diseases of the European Society of Cardioligy (ESC) and of the European Assotiation for the study of Diabetes (EADE). European Heart Journal, 28 (1), 88–136.
  7. Schillaci, G., Verdecchia, P., Porcellati, C., Cuccurullo, O., Cosco, C., Perticone, F. (2000). Continuous Relation Between Left Ventricular Mass and Cardiovascular Risk in Essential Hypertension. Hypertension, 35 (2), 580–586. doi: 10.1161/01.hyp.35.2.580
  8. Vakili, B. A., Okin, P. M., Devereux, R. B. (2001). Prognostic implications of left ventricular hypertrophy. American Heart Journal, 141 (3), 334–341. doi: 10.1067/mhj.2001.113218
  9. Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S. еt. al. (2012). Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. Journal of the American College of Cardiology, 60 (14), 1249–1256. doi: 10.1016/j.jacc.2012.04.053
  10. De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2011). The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 272 (1), 55–64. doi: 10.1111/j.1365-2796.2011.02476.x
  11. Van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A. et. al. (2013). Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH. Circulation: Heart Failure, 6 (2), 219–226. doi: 10.1161/circheartfailure.112.000129
  12. Barrow, H., Rhodes, J. M., Yu, L.-G. (2012). Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cellular Oncology, 36 (1), 9–13. doi: 10.1007/s13402-012-0109-1
  13. Vereecken, P., Awada, A., Suciu, S., Castro, G., Morandini, R., Litynska, A. et. al. (2009). Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Research, 19 (5), 316–320. doi: 10.1097/cmr.0b013e32832ec001
  14. McCullough, P. A., Olobatoke, A., Vanhecke, T. E. (2011). Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Reviews in Cardiovascular Medicine, 12 (4), 200–210.
  15. Mensah-Brown, E. P. K., Al Rabesi, Z., Shahin, A., Al Shamsi, M., Arsenijevic, N., Hsu, D. K. et. al. (2009). Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clinical Immunology, 130 (1), 83–88. doi: 10.1016/j.clim.2008.08.024
  16. Pejnovic, N. N., Pantic, J. M., Jovanovic, I. P., Radosavljevic, G. D., Milovanovic, M. Z., Nikolic, I. G. et. al. (2013). Galectin-3 Deficiency Accelerates High-Fat Diet-Induced Obesity and Amplifies Inflammation in Adipose Tissue and Pancreatic Islets. Diabetes, 62 (6), 1932–1944. doi: 10.2337/db12-0222
  17. Saksida, T., Nikolic, I., Vujicic, M., Nilsson, U. J., Leffler, H., Lukic, M. L. et. al. (2013). Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. Journal of Cellular Physiology, 228 (7), 1568–1576. doi: 10.1002/jcp.24318
  18. Darrow, A. L., Shohet, R. V., Maresh, J. G. (2011). Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiological Genomics, 43 (20), 1144–1152. doi: 10.1152/physiolgenomics.00035.2011
  19. Karlsen, A. E., Storling, Z. M., Sparre, T., Larsen, M. R., Mahmood, A., Storling, J. et. al. (2006). Immune-mediated β-cell destruction in vitro and in vivo–A pivotal role for galectin-3. Biochemical and Biophysical Research Communications, 344 (1), 406–415. doi: 10.1016/j.bbrc.2006.03.105
  20. Pugliese, G., Iacobini, C., Ricci, C., Fantauzzi, C. B., Menini, S. (2014). Galectin-3 in diabetic patients. Clinical Chemistry and Laboratory Medicine, 52 (10), 1413–1423. doi: 10.1515/cclm-2014-0187
  21. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28 (7), 412–419. doi: 10.1007/bf00280883
  22. Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. (1998). Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. New England Journal of Medicine, 339 (4), 229–234. doi: 10.1056/nejm199807233390404
  23. Yokoyama, H., Katakami, N., Yamasaki, Y. (2014). Recent Advances of Intervention to Inhibit Progression of Carotid. J. H., (1), 41–46.
  24. Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S. et. al. (2002). Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature, 421 (6921), 384–388. doi: 10.1038/nature01339
  25. Thakur, V., Reisin, E., Richards, R. (2001). Obesity, Hypertension, and the Heart. The American Journal of the Medical Sciences, 321 (4), 242–248. doi: 10.1097/00000441-200104000-00005
  26. Kahn, B. B., Flier, J. S. (2000). Obesity and insulin resistance. Journal of Clinical Investigation, 106 (4), 473–481. doi: 10.1172/jci10842
  27. Cailar, G. du, Pasquie, J. L., Ribstein, J., Mimran, A. (2000). Left ventricular adaptation to hypertension and plasma renin activity. Journal of Human Hypertension, 14 (3), 181–188. doi: 10.1038/sj.jhh.1000974
  28. Seferovic, J. P., Lalic, N. M., Floridi, F., Tesic, M., Seferovic, P. M., Giga, V. et. al. (2014). Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. Clinical Chemistry and Laboratory Medicine, 52 (10), 1499–505. doi: 10.1515/cclm-2014-0265
  29. Yilmaz, H., Cakmak, M., Inan, O., Darcin, T., Akcay, A. (2014). Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? Journal of Endocrinological Investigation, 38 (5), 527–533. doi: 10.1007/s40618-014-0222-2
  30. De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2011). The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 272 (1), 55–64. doi: 10.1111/j.1365-2796.2011.02476.x
  31. Ohkura, T., Fujioka, Y., Nakanishi, R., Shiochi, H., Sumi, K., Yamamoto, N. et. al. (2014). Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome, 6 (1), 106. doi: 10.1186/1758-5996-6-106
  32. Ozturk, D., Celik, O., Satilmis, S., Aslan, S., Erturk, M., Cakmak, H. A. et. al. (2015). Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coronary Artery Disease, 26 (5), 396–401. doi: 10.1097/mca.0000000000000252
  33. Meluzin, J., Tomandl, J. (2015). Can Biomarkers Help to Diagnose Early Heart Failure with Preserved Ejection Fraction? Disease Markers, 2015, 42–60. doi: 10.1155/2015/426045

Downloads

Published

2017-05-31

How to Cite

Bilovol, O., & Bobrotonnikova, L. (2017). Prognostic role of biomarker-glycoprotein in diagnostics of pathological changes in patients with arterial hypertension and diabetes mellitus 2 type. ScienceRise: Medical Science, (5 (13), 4–9. https://doi.org/10.15587/2519-4798.2017.102545

Issue

No. 5 (13) (2017)

Section

Medical Science

License

Copyright (c) 2017 Olexandr Bilovol, Lesya Bobrotonnikova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.